Last reviewed 2026-04-22 · How we verify

CsA+Rapamune+CS

This triple immunosuppressive regimen combines calcineurin inhibition, mTOR inhibition, and corticosteroid activity to prevent organ rejection by suppressing T-cell activation and proliferation.

This triple immunosuppressive regimen combines calcineurin inhibition, mTOR inhibition, and corticosteroid activity to prevent organ rejection by suppressing T-cell activation and proliferation. Used for Organ transplant rejection prophylaxis (renal, cardiac, hepatic transplantation).

At a glance

Mechanism of action

Cyclosporine A (CsA) inhibits calcineurin, blocking T-cell receptor signaling and IL-2 production. Rapamune (sirolimus) inhibits mTOR, preventing T-cell proliferation and differentiation. Corticosteroids (CS) provide broad immunosuppression by reducing inflammatory cytokine production and immune cell activation. Together, these agents target multiple pathways in the immune response to prevent allograft rejection.

Approved indications

• Organ transplant rejection prophylaxis (renal, cardiac, hepatic transplantation)

Common side effects

• Nephrotoxicity
• Hypertension
• Hyperglycemia
• Hyperlipidemia
• Infection
• Tremor
• Gingival hyperplasia

Key clinical trials

• SCHEDULE Follow Up Visit 5-7 yr (PHASE4)
• Open Label Comparative Study Of De Novo Renal Allograft Recipients Receiving CSA + MMF + Corticosteroids Versus CSA + Rapamune + Corticosteroids (PHASE4)
• SCHEDULE - Scandinavian Heart Transplant Everolimus de Novo Study With Early Calcineurin Inhibitor (CNI) Avoidance (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.